CTOs on the Move

True North Therapeutics

www.truenorthrx.com

 
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The companys lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, renal, and neurological space. True North was formed in 2013 as a spin-out of iPierian.
  • Number of Employees: 5K-10K
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

True North Therapeutics raised $40M on 12/03/2015
True North Therapeutics raised $45M on 10/19/2016

Similar Companies

Capricor

Los Angeles-based Capricor is a privately held biotechnology company that aims to create powerful, yet easy-to-administer cardiac stem cell treatments to regenerate damaged heart muscle and improve heart function for patients having suffered a heart attack.

Capital Genomix (US Headquarters)

Capital Genomix (US Headquarters) is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CMAC Consultancy

CMAC Consultancy is a Vernon Hills, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Employers Drug Program Management

Employers Drug Program Management is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Receptor Life Sciences

Receptor Life Sciences, Inc. develops inhaled therapeutic products for conditions including chronic pain, neurologic diseases, and inflammatory disorders.